Literature DB >> 27837786

Connections between pharmacoepidemiology and cancer biology: designing biologically relevant studies of cancer outcomes.

Donna R Rivera1, Katherine A McGlynn2, Andrew N Freedman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27837786      PMCID： PMC5765753          DOI： 10.1016/j.annepidem.2016.10.001

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN： 1047-2797            Impact factor:   3.797


× No keyword cloud information.
  12 in total

Review 1.  Identifying health outcomes in healthcare databases.

Authors:  Stephan Lanes; Jeffrey S Brown; Kevin Haynes; Michael F Pollack; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-08-18       Impact factor: 2.890

Review 2.  Validity of composite end points in clinical trials.

Authors:  Victor M Montori; Gaietà Permanyer-Miralda; Ignacio Ferreira-González; Jason W Busse; Valeria Pacheco-Huergo; Dianne Bryant; Jordi Alonso; Elie A Akl; Antònia Domingo-Salvany; Edward Mills; Ping Wu; Holger J Schünemann; Roman Jaeschke; Gordon H Guyatt
Journal:  BMJ       Date:  2005-03-12

3.  Sustained lower rates of breast cancer in the United States.

Authors:  Kathleen A Cronin; Peter M Ravdin; Brenda K Edwards
Journal:  Breast Cancer Res Treat       Date:  2008-11-01       Impact factor: 4.872

4.  Identification of esophageal cancer in the General Practice Research Database.

Authors:  Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-09-16       Impact factor: 2.890

5.  VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

Authors:  Diether Lambrechts; Bart Claes; Paul Delmar; Joke Reumers; Massimiliano Mazzone; Betül T Yesilyurt; Roland Devlieger; Chris Verslype; Sabine Tejpar; Hans Wildiers; Sanne de Haas; Peter Carmeliet; Stefan J Scherer; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2012-05-17       Impact factor: 41.316

6.  The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Authors:  Athina Giannoudis; Lihui Wang; Andrea L Jorgensen; George Xinarianos; Andrea Davies; Sudeep Pushpakom; Triantafilos Liloglou; Jieying-Eunice Zhang; Gemma Austin; Tessa L Holyoake; Letizia Foroni; Panagiotis D Kottaridis; Martin C Müller; Munir Pirmohamed; Richard E Clark
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

Review 7.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

8.  Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.

Authors:  Reina Haque; Syed A Ahmed; Galina Inzhakova; Jiaxiao Shi; Chantal Avila; Jonathan Polikoff; Leslie Bernstein; Shelley M Enger; Michael F Press
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-09-18       Impact factor: 4.254

9.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

10.  Trends in Prescription Drug Use Among Adults in the United States From 1999-2012.

Authors:  Elizabeth D Kantor; Colin D Rehm; Jennifer S Haas; Andrew T Chan; Edward L Giovannucci
Journal:  JAMA       Date:  2015-11-03       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.